Healthcare, Pharma & Life Sciences

Hagens Berman Probes Aardvark Therapeutics Over ARD-101 Safety Disclosures

Image
Hagens Berman Probes Aardvark Therapeutics Over ARD-101 Safety Disclosures

San Francisco – September 10, 2026 -- Hagens Berman Sobol Shapiro LLP has opened an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) over allegations that the company misled investors about the safety of its lead drug candidate ARD-101, ahead of an October 13, 2026 deadline for shareholders to seek lead plaintiff status in a pending securities class action.

Investors who bought Aardvark stock between February 13, 2025 and May 14, 2026 are covered by the class period

The lawsuit targets purchasers who acquired shares pursuant to Aardvark's February 13, 2025 initial public offering, as well as those who bought securities through May 14, 2026. The complaint alleges the company's offering documents failed to disclose that ARD-101 was significantly less safe than represented, including reversible cardiac observations such as QRS prolongation at above-target doses during clinical trials.

Hims & Hers Faces Securities Suit After FTC Data-Sharing Complaint

Image
Hims & Hers Faces Securities Suit After FTC Data-Sharing Complaint

San Francisco – September 10, 2026 -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain executives now face a securities class action after a July 29, 2026 federal complaint from the Federal Trade Commission wiped over $970 million from the company's market capitalization in a single trading session, sending shares down $4.32, or 14.7%.

FTC alleges Hims shared health data with Meta and Snap despite privacy pledges

The FTC complaint, filed alongside co-plaintiffs the State of Utah and Los Angeles County representing California, accuses Hims of surreptitiously sharing sensitive user medical conditions and personal health data with third-party advertising platforms including Meta Platforms and Snap. Regulators allege the company used embedded tracking pixels and customer list matching to transmit this data, contradicting public assurances that it maintained administrative, physical, and technical safeguards for health and personal information.

Wooree Group Pushes 'Six Pillars' Standard for Liposome Health Products

Image
Wooree Group Pushes 'Six Pillars' Standard for Liposome Health Products

Bangkok -- September 10, 2026 -- Wooree Group, a South Korean biotechnology and lighting conglomerate with 60 years of history, has called for a scientific validation standard for the liposomal health products market, following its participation in Vitafoods Asia 2026 held September 2-4 in Bangkok.

Korea's MFDS Closes GBC 2026 With 5,600 Attendees, 23 Regulator Meetings

Seoul – September 10, 2026 -- The Ministry of Food and Drug Safety of Korea (MFDS) concluded the 12th Global Bio Conference (GBC) on August 28, drawing roughly 5,600 participants from 19 countries to the Grand InterContinental Seoul Parnas for three days of talks on biopharmaceutical regulation and technology.

Forums drew hundreds of specialists across vaccines, proteins and advanced therapies

Held from August 26-28 under the theme 'The Great Leap in Bio, Accelerating Innovation,' the event featured 75 biopharmaceutical experts delivering presentations across specialized tracks. The Recombinant Protein Products Forum attracted 591 attendees, the Advanced Biopharmaceuticals Policy and Quality Forum drew 483, and the Vaccine Forum logged 462 participants, combining online and offline sessions.

AtomVie Opens $160M Radiopharma Plant in Hamilton, Ontario

Image
AtomVie Opens $160M Radiopharma Plant in Hamilton, Ontario

Hamilton, Ontario – – September 10, 2026 -- AtomVie Global Radiopharma has officially opened a new manufacturing plant at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest contract development and manufacturing organization (CDMO) site in North America dedicated to radiopharmaceutical production.

Facility spans 6,700 square meters and multiplies output tenfold

The site covers more than 6,700 square meters and increases AtomVie's production capacity by more than tenfold, supporting variable low-to-high throughput manufacturing. Modular spaces are designed to allow a smooth transition from early-stage clinical development to full commercial-scale production of radiopharmaceuticals.

AtomVie Opens $160M Radiopharma Plant, 10x Capacity in Ontario

Image
AtomVie Opens $160M Radiopharma Plant, 10x Capacity in Ontario

Hamilton, Ontario – September 10, 2026 -- AtomVie Global Radiopharma has opened a new 72,300-square-foot production facility at 10 Aeropark Boulevard in Hamilton, Ontario, backed by more than $160 million in investment and marking the largest single-site radiopharmaceutical CDMO facility in North America.

New facility multiplies AtomVie's manufacturing output tenfold

The purpose-built plant increases AtomVie's production capacity by a factor of ten, supporting both low- and high-throughput manufacturing. The site is designed to handle the full lifecycle of radiopharmaceutical production, from early-stage clinical development through commercial-scale manufacturing, with flexible space reserved for future client requirements.

Six Proteomic Clocks Confirm Insilico's AI Drug Reverses Biological Age

Cambridge, Massachusetts – September 10, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.

ABDA Sets Munich Press Briefing on Pharmacy Reform Impact

Image
ABDA Sets Munich Press Briefing on Pharmacy Reform Impact

Munich – September 10, 2026 -- More than 300 delegates from Germany's 17 pharmacist chambers and associations will convene in Munich from September 15 to 17 for the German Pharmacists' Day (Deutscher Apothekertag, DAT) 2026, as the country's pharmacy reform moves from legislation into implementation.

CelluPro Becomes First China Firm With EXCiPACT GMP Media Certification

Yantai – September 10, 2026 -- CelluPro has become the first Chinese cell culture media supplier to receive EXCiPACTTM GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), a credential aimed at strengthening its position in global biomanufacturing supply chains.

EXCiPACT certification sets an internationally recognized GMP benchmark for cell culture media suppliers

The EXCiPACTTM scheme establishes GMP requirements for materials used in biopharmaceutical manufacturing, providing an independent framework to assess quality management, manufacturing controls, traceability, and supply chain practices. For CelluPro, the certification adds to an existing quality portfolio that includes ISO 9001, ISO 13485, ISO 14001, ISO 45001, and ISO 22301 certifications covering quality, environmental, occupational health and safety, and business continuity management.

CelluPro Becomes First China Cell Culture Media Maker With EXCiPACT GMP

Yantai – September 10, 2026 -- CelluPro has secured EXCiPACTTM GMP certification for pharmaceutical auxiliary materials, becoming the first China-based cell culture media supplier to achieve the credential.

CelluPro adds EXCiPACT GMP to existing ISO certification portfolio

The biotechnology firm, which specializes in serum-free cell culture media and bioprocessing solutions, now holds EXCiPACTTM certification alongside ISO 9001, ISO 13485, ISO 14001, ISO 45001 and ISO 22301 certifications covering quality management, environmental management, occupational health and safety, and business continuity.